Cardiome Receives Brinavess Approval in Turkey

Cardiome Pharma Corp.‘s Brinavess has been approved in Turkey by the Turkish Ministry of Health for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

“We are pleased to receive approval for Brinavess in Turkey,” said Karim Lalji, Cardiome’s chief commercial officer. “This decision confirms Cardiome’s commitment to pursue Brinavess approvals beyond the EU region. We will seek a local distribution partnership in this key market in order to optimize the commercialization and launch and make Brinavess available for the benefit of patients suffering from AF.”

According to the European Federation of Pharmaceutical Industry and Associations Pharmaceutical Industry Report, total sales for the pharmaceutical market in Turkey totaled $9.7 billion in 2011.